ALEXANDRIA, Va. – The latest research exploring innovative approaches for the detection and treatment of prostate, bladder, and kidney cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 700 abstracts that will be presented at the meeting.

The Symposium, taking place January 25-27 in San Francisco, California and online, will bring together the global GU cancer community to discuss the latest advances in patient care across all GU disease sites and treatment modalities. 

The majority of abstracts will be publicly released on ASCO.org/gu-abstracts on Monday, January 22 2024, at 5:00 PM (ET); late-breaking abstracts (LBAs) will publicly released at 10:00 AM (ET) on the day of presentation at the meeting and the embargoes will lift at those times. Press releases on the following abstracts will be made available to reporters covering the meeting:

• Overall survival results from the phase III KEYNOTE-564 trial examining adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma. (Abstract LBA359)
• Results from the phase III CONTACT-2 study evaluating cabozantinib plus atezolizumab compared to second novel hormonal therapy for metastatic castration-resistant prostate cancer. (Abstract 18)

A tip sheet with additional insights from study authors and ASCO experts on the studies below will also be made available to reporters covering the meeting:

• Results of the GETUG-AFU 18 phase III randomized trial examining the long-term results of dose escalation combined with long-term androgen deprivation in patients with high-risk prostate cancers. (Abstract LBA259)
• The part B results of the phase III CheckMate 914 trial studying adjuvant nivolumab monotherapy for localized renal cell carcinoma at high risk of relapse after nephrectomy. Abstract LBA358)
• Results from the CheckMate 67T study evaluating subcutaneous nivolumab compared to intravenous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma. (Abstract LBA360)
• Findings from the randomized, phase III AMBASSADOR Alliance A031501 study of pembrolizumab in patients with muscle-invasive and locally advanced urothelial carcinoma. (Abstract LBA531)
• A prospective study examining remote delivery of cancer genetic testing in veterans with metastatic prostate cancer. (Abstract 60)
• Results from a multicenter, randomized trial evaluating transperineal versus transrectal prostate biopsy to prevent infection complications. (Abstract 261)
• A prospective trial assessing prostate cancer detection with the Stockholm3 blood test in a multi-ethnic cohort. (Abstract 262)
• Prostate cancer screening recommendations for Black men in the United States based on the results of a comprehensive literature review by the Prostate Cancer Foundation. (Abstract 264)
• A study examining the effect of dual Medicare- and Medicaid-eligible benefits on the quality of care in men newly diagnosed with prostate cancer on active surveillance (Abstract 266)

MEDIA RESOURCES

Apply for/renew ASCO media credentials: Reporters with valid ASCO media credentials will be able to access embargoed press materials and view online presentations from the 2024 ASCO Genitourinary Cancers Symposium. Please visit ASCO’s Media Headquarters (HQ) at mediahq.asco.org to request credentials or to ensure your credentials are up to date.

Attend the Symposium in person: Credentialed media who would like to attend the meeting in-person can register and/or reserve a hotel room through ASCO’s Media HQ. To register:

• Sign in to your ASCO Media HQ account at mediahq.asco.org
• Click on the “In-Person Registration and Hotel Reservations” tile